Cargando…
What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It?
On September 18, 2007, a collaborative session between the International Society for CNS Clinical Trials and Methodology and the International Society for CNS Drug Development was held in Brussels, Belgium. Both groups, with membership from industry, academia, and governmental and nongovernmental ag...
Autores principales: | Kemp, Aaron S., Schooler, Nina R., Kalali, Amir H., Alphs, Larry, Anand, Ravi, Awad, George, Davidson, Michael, Dubé, Sanjay, Ereshefsky, Larry, Gharabawi, Georges, Leon, Andrew C., Lepine, Jean-Pierre, Potkin, Steven G., Vermeulen, An |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2879679/ https://www.ncbi.nlm.nih.gov/pubmed/18723840 http://dx.doi.org/10.1093/schbul/sbn110 |
Ejemplares similares
-
Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?
por: Alphs, Larry, et al.
Publicado: (2012) -
COVID-19 in Iran: What was done and what should be done
por: Nojomi, Marzieh, et al.
Publicado: (2021) -
Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: Data from a randomized double-blind trial
por: Gharabawi, Georges M, et al.
Publicado: (2006) -
What Art Has Done for Dentistry—and What Dentistry Has Done for Art
por: Cigrand, B. J.
Publicado: (1902) -
Biodegradable Iron-Based Materials—What Was Done and What More Can Be Done?
por: Gąsior, Gabriela, et al.
Publicado: (2021)